Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07132008) titled 'Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer' on Aug. 13.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: First Affiliated Hospital of Guangxi Medical University
Condition:
Colonic Neoplasms
Neoadjuvant Therapy
Immune Checkpoint Inhibitors
Intervention:
Drug: Tislelizumab
Drug: Oxaliplatin
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: October 1, 2025
Target Sample Size: 94
Countries of Recruitment:...